| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Nicholas A Meanwell | |
| Kap-Sun Yeung | |||
| Gregory A Yamanaka | |||
| P2860 | cites work | A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase | Q22254730 |
| A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 | Q24290169 | ||
| ACE2: from vasopeptidase to SARS virus receptor | Q24294404 | ||
| CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus | Q24307914 | ||
| pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN | Q24563490 | ||
| The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex | Q27477706 | ||
| Structural basis for paramyxovirus-mediated membrane fusion | Q27617867 | ||
| Structural characterization of the human respiratory syncytial virus fusion protein core | Q27628799 | ||
| ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis | Q27643059 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| The HIV Env-mediated fusion reaction | Q28188544 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| Angiotensin-converting enzyme 2 is an essential regulator of heart function | Q28205840 | ||
| Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection | Q28588877 | ||
| Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage | Q29615331 | ||
| Mechanisms of viral membrane fusion and its inhibition | Q29616090 | ||
| The Genome sequence of the SARS-associated coronavirus | Q29619007 | ||
| Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus | Q37421234 | ||
| Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor | Q37423228 | ||
| Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. | Q37511480 | ||
| Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells | Q37567824 | ||
| Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion | Q37585515 | ||
| Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein | Q39992400 | ||
| Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein | Q40436586 | ||
| Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies | Q40437929 | ||
| Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. | Q40471278 | ||
| Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine | Q40506063 | ||
| Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. | Q40510688 | ||
| Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression | Q40517315 | ||
| A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice | Q40520942 | ||
| Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor | Q40546105 | ||
| Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein | Q40548165 | ||
| S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients | Q40551623 | ||
| Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein | Q40579430 | ||
| Coronavirus-induced membrane fusion requires the cysteine-rich domain in the spike protein | Q40892854 | ||
| Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents | Q42716746 | ||
| Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. | Q44000915 | ||
| Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors | Q44217290 | ||
| Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein | Q44985460 | ||
| Infectious diseases. One year after outbreak, SARS virus yields some secrets | Q45637990 | ||
| Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core | Q45643870 | ||
| Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors | Q45659807 | ||
| Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases | Q47242360 | ||
| Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). | Q47278854 | ||
| Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets | Q47283945 | ||
| The SARS-CoV S glycoprotein: expression and functional characterization | Q47346882 | ||
| Identification of two antigenic epitopes on SARS-CoV spike protein | Q47378590 | ||
| A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. | Q47774466 | ||
| The aromatic domain of the coronavirus class I viral fusion protein induces membrane permeabilization: putative role during viral entry | Q47863927 | ||
| Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus | Q47902789 | ||
| Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. | Q47924234 | ||
| Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines | Q47930004 | ||
| Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core | Q47932220 | ||
| An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 | ||
| Structural characterization of the SARS-coronavirus spike S fusion protein core. | Q48009341 | ||
| Early events of SARS coronavirus infection in vero cells. | Q51654795 | ||
| Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein | Q56762915 | ||
| Severe acute respiratory syndrome | Q56775278 | ||
| A model of the ACE2 structure and function as a SARS-CoV receptor. | Q64924413 | ||
| Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain | Q80457043 | ||
| Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) | Q81481064 | ||
| Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. | Q30336102 | ||
| Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism | Q30775494 | ||
| Expression cloning of functional receptor used by SARS coronavirus | Q31041420 | ||
| Novel peptide inhibitors of angiotensin-converting enzyme 2. | Q31133376 | ||
| B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein | Q31149856 | ||
| Potential for antiviral treatment of severe acute respiratory syndrome | Q33195130 | ||
| The life cycle of SARS coronavirus in Vero E6 cells | Q33203307 | ||
| The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells | Q33207348 | ||
| Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus | Q33210858 | ||
| Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein | Q33581892 | ||
| Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses | Q33756740 | ||
| Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants | Q33780455 | ||
| Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein | Q33788831 | ||
| Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. | Q33834543 | ||
| Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry | Q33920306 | ||
| T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. | Q34151667 | ||
| Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Q34376025 | ||
| Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice | Q34385350 | ||
| An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies | Q34437463 | ||
| Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies | Q34438091 | ||
| Structure of SARS coronavirus spike receptor-binding domain complexed with receptor | Q34451350 | ||
| Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. | Q34514760 | ||
| Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection | Q35124942 | ||
| SARS coronavirus: a new challenge for prevention and therapy | Q35143451 | ||
| SARS--beginning to understand a new virus | Q35701656 | ||
| Molecular biology of severe acute respiratory syndrome coronavirus | Q35883052 | ||
| Cellular entry of the SARS coronavirus | Q35894137 | ||
| The SARS-CoV S glycoprotein | Q35938995 | ||
| Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor | Q36024617 | ||
| Current status of anti-SARS agents | Q36058652 | ||
| Development of antiviral therapy for severe acute respiratory syndrome. | Q36119173 | ||
| Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association | Q36602721 | ||
| Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice | Q37010921 | ||
| Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry | Q37356916 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 414-433 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Medicinal Research Reviews | Q2436033 |
| P1476 | title | Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention | |
| P478 | volume | 26 |
| Q81615402 | A second SARS-CoV S2 glycoprotein internal membrane-active peptide. Biophysical characterization and membrane interaction |
| Q40231729 | Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization |
| Q46287563 | Expression of SARS-coronavirus spike glycoprotein in Pichia pastoris |
| Q40030137 | Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors |
| Q35670097 | Impaired angiogenesis in aminopeptidase N-null mice |
| Q34009523 | Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans |
| Q58290652 | Interaction of a Peptide from the Pre-transmembrane Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein with Phospholipid Membranes |
| Q37929687 | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential |
| Q87461608 | Potential interventions for novel coronavirus in China: A systematic review |
| Q94589436 | Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19) |
| Q33897964 | Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody |
| Q92053517 | Therapeutic strategies for critically ill patients with COVID-19 |
Search more.